Skip to main content
OpenTrials

Clinical trial condition

Gastroesophageal Adenocarcinoma

Explore clinical trials studying Gastroesophageal Adenocarcinoma. Study availability and eligibility vary by location and protocol.

26 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Gastroesophageal Adenocarcinoma trial results

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastroesophageal Adenocarcinoma, +6 more
Locations
  • Research Site Newark, Delaware, United States
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Fairway, Kansas, United States
  • Research Site North Shores, Michigan, United States
View all 70 locations
View Trial Details
Recruiting

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

NCT06043427

Conditions
Gastroesophageal Adenocarcinoma
Locations
  • Arthur J.E. Child Comprehensive Cancer Centre Calgary, Alberta, Canada
  • BCCA - Vancouver Vancouver, British Columbia, Canada
  • CancerCare Manitoba Winnipeg, Manitoba, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
View all 18 locations
View Trial Details
Recruiting

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944

Conditions
Digestive System Diseases, Digestive System Neoplasms, Esophageal Cancer, +10 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 6905) Los Angeles, California, United States
  • Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900) Louisville, Kentucky, United States
  • The Cancer and Hematology Centers ( Site 6912) Grand Rapids, Michigan, United States
View all 51 locations
View Trial Details
Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

NCT06445972

Conditions
Digestive System Diseases, Digestive System Neoplasms, Esophageal Cancer, +10 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 8905) Los Angeles, California, United States
  • Norton Cancer Institute - Downtown ( Site 8900) Louisville, Kentucky, United States
  • The Cancer and Hematology Centers ( Site 8912) Grand Rapids, Michigan, United States
View all 47 locations
View Trial Details
Recruiting

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

NCT07176312

Conditions
Digestive System Diseases, Digestive System Neoplasms, First Line Therapy, +14 more
Locations
  • Charité CVK Berlin, Germany
  • Vivantes Klinikum im Friedrichshain Berlin, Germany
  • Klinikum Bielefeld Bielefeld, Germany
  • Städtisches Klinikum Dresden Dresden, Germany
View all 20 locations
View Trial Details

Related conditions